We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Exagen Inc | NASDAQ:XGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0 | - |
From Jun 2023 to Jun 2024
By Denny Jacob
Exagen agreed to pay $650,143 to resolve allegations it paid specimen processing fees to referring physicians to induce their use of the company's laboratory tests.
The commercial-stage diagnostics company agreed to factual admissions that it paid certain referring physicians to complete blood draws for patients in connection to specimen processing agreements that Exagen entered into with those physicians, according to the Department of Justice.
Exagen billed federal healthcare programs, including Medicare, for tests it performed after receiving orders from the physicians, according to the settlement. The company did so even after becoming aware of a fraud alert in June from the Department of Health & Human Services' Office of the Inspector General.
DOJ said the settlement stems from allegations brought in a lawsuit filed by a whistleblower, who will receive 16% of the recovered settlement.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
October 17, 2023 14:35 ET (18:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Exagen Chart |
1 Month Exagen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
